{"id":72196,"date":"2026-08-10T13:48:09","date_gmt":"2026-08-10T05:48:09","guid":{"rendered":"https:\/\/flcube.com\/?p=72196"},"modified":"2026-08-10T13:48:09","modified_gmt":"2026-08-10T05:48:09","slug":"chinas-12th-national-vbp-round-officially-confirmed-490-enterprises-selected-as-planned-procurement-value-shrinks-over-one-third-to-rmb-19-5-billion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72196","title":{"rendered":"China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One\u2011Third to RMB 19.5 Billion"},"content":{"rendered":"\n

The Joint Procurement Office<\/strong> published the official winning results<\/strong> for the 12th batch of National Volume\u2011Based Drug Procurement (VBP)<\/strong>, aligning with the preliminary selection results. Counted by parent company, a total of 490 pharmaceutical enterprises<\/strong> were selected, including 6 originator brand companies<\/strong>.<\/p>\n\n\n\n

Results Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Round<\/strong><\/td>12th batch of National Volume\u2011Based Drug Procurement (VBP)<\/td><\/tr>
Publishing Body<\/strong><\/td>Joint Procurement Office<\/td><\/tr>
Publication Date<\/strong><\/td>6 Aug 2026<\/td><\/tr>
Comparison with Preliminary Results<\/strong><\/td>Aligned<\/td><\/tr>
Enterprises Selected<\/strong><\/td>490 (counted by parent company)<\/td><\/tr>
Originator Participation<\/strong><\/td>6 originator brand companies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Notable Departures From Previous Rounds<\/h2>\n\n\n\n

Departing from previous VBP rounds, this official announcement omits drug specifications, winning prices, and assigned supply regions<\/strong> \u2014 a break in disclosure practice that leaves market participants without the granular pricing and regional allocation detail typically released alongside VBP results.<\/p>\n\n\n\n

Market Size & Procurement Value<\/h2>\n\n\n\n
Metric<\/th>Figure<\/th><\/tr><\/thead>
Pre\u2011procurement market size (shortlisted drug candidates)<\/strong><\/td>Nearly RMB 60 billion (per public market data)<\/td><\/tr>
Total planned procurement value (estimate)<\/strong><\/td>RMB 19.5 billion<\/td><\/tr>
Implied shrinkage<\/strong><\/td>Over one\u2011third<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Based on estimates using maximum valid bids and demand quantities<\/strong>, the total planned procurement value reached RMB 19.5 billion<\/strong> \u2014 a shrink of over one\u2011third<\/strong> against the nearly RMB 60 billion pre\u2011procurement market size for the shortlisted drug candidates.<\/p>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n